ACH 126445

Drug Profile

ACH 126445

Alternative Names: L-OddU

Latest Information Update: 01 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Achillion Pharmaceuticals
  • Class Antivirals; Nucleosides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Epstein-Barr virus infections; Infectious mononucleosis; Nasopharyngeal cancer; Post-transplant lymphoproliferative disorder

Most Recent Events

  • 03 Sep 2002 Preclinical trials in Post-transplant lymphoproliferative disorder in USA (unspecified route)
  • 03 Sep 2002 Preclinical trials in Infectious mononucleosis in USA (unspecified route)
  • 03 Sep 2002 Preclinical trials in Nasopharyngeal cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top